Autolus Therapeutics plc (AUTL)
- Previous Close
4.2100 - Open
4.5200 - Bid 4.0800 x 300
- Ask 4.1000 x 300
- Day's Range
3.9600 - 4.2900 - 52 Week Range
1.6900 - 7.4500 - Volume
3,872,781 - Avg. Volume
1,595,283 - Market Cap (intraday)
1.085B - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2000 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.69
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.
www.autolus.comRecent News: AUTL
Performance Overview: AUTL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AUTL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AUTL
Valuation Measures
Market Cap
1.08B
Enterprise Value
898.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
417.95
Price/Book (mrq)
9.73
Enterprise Value/Revenue
529.08
Enterprise Value/EBITDA
-5.73
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.35%
Return on Equity (ttm)
-101.61%
Revenue (ttm)
1.7M
Net Income Avi to Common (ttm)
-208.38M
Diluted EPS (ttm)
-1.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
239.57M
Total Debt/Equity (mrq)
200.82%
Levered Free Cash Flow (ttm)
-125.13M